Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SON 1210

Next Previous
Drug Profile

SON 1210

Alternative Names: IL15-FHAB-IL12; SON-1210

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sonnet Biotherapeutics
  • Developer Sarcoma Oncology Research Center; Sonnet BioTherapeutics Holdings, Inc
  • Class Antineoplastics; Immunoglobulin Fv fragments; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 12 replacements; Interleukin 15 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pancreatic cancer; Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
  • 28 Jan 2025 European Patent Office (EPO) grants Patent No. EP3583125 B1, entitled ”Albumin Binding Domain Fusion Proteins,” which covers Sonnet’s Fully Human Albumin Binding (FHAB®) technology and includes therapeutic fusion proteins that utilize FHAB
  • 18 Dec 2024 Pharmacodynamics data from a preclinical studies in Solid tumours released by Sonnet Biotherapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top